FibroBiologics, Common Stock Forecast - Daily Balance Of Power
| FBLG Stock | 2.84 0.19 7.17% |
FibroBiologics, Stock Forecast is based on your current time horizon. We recommend always using this module together with an analysis of FibroBiologics, Common's historical fundamentals, such as revenue growth or operating cash flow patterns.
FibroBiologics, |
| Check FibroBiologics, Common Volatility | Backtest FibroBiologics, Common | Information Ratio |
FibroBiologics, Common Trading Date Momentum
| On October 05 2024 FibroBiologics, Common Stock was traded for 2.84 at the closing time. The top price for the day was 2.89 and the lowest listed price was 2.64 . There was no trading activity during the period 0.0. Lack of trading volume on October 5, 2024 did not affect price variability. The overall trading delta against the current closing price is 4.23% . |
Balance of Power indicator was created by Igor Livshin to predict asset short term price movements or warning signals. If Balance of Power indicator is trended towards the high of its range it will signify that the bulls are in control. On the other hand when the BOP indicator is moving towards the lows of its range it signifies that the bears are in control. If the indicator move from a high positive range to a lower positive range it signifies that the buying pressure is decreasing. Conversely, if the indicator move from a low negative range to a higher negative range it signifies that the selling pressure is decreasing.
| Compare FibroBiologics, Common to competition |
Other Forecasting Options for FibroBiologics, Common
For every potential investor in FibroBiologics,, whether a beginner or expert, FibroBiologics, Common's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. FibroBiologics, Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in FibroBiologics,. Basic forecasting techniques help filter out the noise by identifying FibroBiologics, Common's price trends.FibroBiologics, Common Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with FibroBiologics, Common stock to make a market-neutral strategy. Peer analysis of FibroBiologics, Common could also be used in its relative valuation, which is a method of valuing FibroBiologics, Common by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
FibroBiologics, Common Technical and Predictive Analytics
The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of FibroBiologics, Common's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of FibroBiologics, Common's current price.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
FibroBiologics, Common Market Strength Events
Market strength indicators help investors to evaluate how FibroBiologics, Common stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading FibroBiologics, Common shares will generate the highest return on investment. By undertsting and applying FibroBiologics, Common stock market strength indicators, traders can identify FibroBiologics, Common Stock entry and exit signals to maximize returns.
FibroBiologics, Common Risk Indicators
The analysis of FibroBiologics, Common's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in FibroBiologics, Common's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting fibrobiologics, stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 7.9 | |||
| Semi Deviation | 11.85 | |||
| Standard Deviation | 12.27 | |||
| Variance | 150.54 | |||
| Downside Variance | 145.36 | |||
| Semi Variance | 140.52 | |||
| Expected Short fall | (7.81) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Currently Active Assets on Macroaxis
| OEF | iShares SP 100 | |
| GLD | SPDR Gold Shares | |
| OIH | VanEck Oil Services | |
| IBB | iShares Biotechnology ETF | |
| IJH | iShares Core SP |
Additional Information and Resources on Investing in FibroBiologics, Stock
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Historical Fundamental Analysis of FibroBiologics, Common to cross-verify your projections. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.62) | Return On Equity (4.34) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.